Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic

Original research
by
Nguyen, Thuy et al

Release Date

2022

Geography

USA

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

Yes

Peer Reviewed

Yes

Objective

Did pandemic disruptions in filled buprenorphine and extended-release naltrexone prescriptions for opioid use disorder (OUD) differ by race and ethnicity or insurance status and payer type?

Findings/Key points

These findings suggest that the COVID-19 pandemic may have been associated with worsened disparities in filled buprenorphine and naltrexone prescriptions for OUD among members of racial and ethnic minority groups compared with White patients.

Design/methods

Cross-sectional study of 92% of US retail pharmacy claims of buprenorphine among 1 556 860 individuals and extended-release naltrexone among 127 506 individuals for OUD from May 2019 to June 2021

Keywords

Equity
Substitution